Boston Scientific CEO Sells 20 Billion Won Stake While Retaining 2 Trillion Won Stake

Boston Scientific Corporation (BSX) today reported its fourth-quarter and full-year 2025 results. Fourth-quarter revenue rose 15.9% year-over-year to $5.286 billion, and full-year sales increased 19.9% to $20.074 billion—approximately KRW 7 trillion and KRW 26 trillion, respectively.

On February 2, Chairman and CEO Michael F. Mahoney exercised two tranches of previously granted stock options, acquiring about 95,000 shares. In accordance with a pre-arranged trading plan, he then sold a portion of his holdings to generate roughly $15 million (approximately KRW 200 billion) in cash. Even after these transactions, Mahoney retains an equity stake—directly and indirectly through trusts—worth about $148 million (around KRW 2 trillion) at current share prices.

Boston Scientific has also moved to broaden its cardiovascular and urology portfolio by signing agreements to acquire Penumbra, a thrombectomy and neurovascular device maker, for about $14.5 billion (KRW 19 trillion), and Valencia Technologies, which markets the eCoin implantable stimulator for urinary incontinence. The company recently closed its acquisition of Nalu Medical and continues to emphasize a growth strategy centered on new product launches and M&A. For 2026, Boston Scientific is guiding revenue growth of 10.5–11.5% and adjusted earnings per share of $3.43–$3.49.

Headquartered in Massachusetts, Boston Scientific is a global medical-device leader offering minimally invasive treatment solutions across cardiovascular, neurovascular, endoscopy, urology, and pelvic-health markets. Since the 1980s, it has grown into one of the world’s largest medtech companies.